Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.63 |
| ▸ | RAF1 | P04049 | 16/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972168 | 0.90 | MAP2K1 (0.78) | MAP2K1RAF1KDM4EALDH1A1KMT2A | |
| SCHEMBL2249678 | 0.88 | MAP2K1 (0.82) | MAP2K1RAF1 | |
| SCHEMBL972660 | 0.82 | MAPT (0.53) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL973637 | 0.80 | MAP2K1 (0.82) | MAP2K1RAF1KDM4EALDH1A1KMT2A | |
| SCHEMBL962917 | 0.78 | MAP2K1 (0.75) | MAP2K1RAF1 | |
| SCHEMBL960175 | 0.78 | MAP2K1 (1.00) | MAP2K1RAF1 | |
| SCHEMBL972746 | 0.77 | MAP2K1 (0.60) | MAP2K1RAF1KDM4EALDH1A1KMT2A | |
| SCHEMBL970908 | 0.75 | MAP2K1 (0.59) | MAP2K1RAF1KDM4EALDH1A1KMT2A | |
| SCHEMBL972380 | 0.74 | MAP2K1 (0.64) | MAP2K1RAF1KDM4EALDH1A1KMT2A | |
| SCHEMBL960942 | 0.74 | MAP2K1 (1.00) | MAP2K1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885RAF1 699/4885KDM4E 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.